BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V}

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BRAVEHEART who wrote (1)	2/20/1999 4:46:00 PM
From: BRAVEHEART	of 423

NTII Update: Review: Message 7069713 UNMET NEEDS... "For every ten patients diagnosed with MS 100 patients are diagnosed with Peripheral Neuropathies." There are 10 million diabetics in the US. I have seen figures which suggest that from 10% to 50% experience some form of Peripheral Neuropathy. Assuming say 20% suggests a 2,000,000 US patient population. Here is some first hand accounts on the search ( personal accounts ) for a treatment that works. boardhost.com neuropathy-trust.org Living with Peripheral Neuropathies... neuropathy-trust.org The potential is certainly significant. Surely the market size is large and wide open for rapid penetration. A 20% penetration would be enormous to NTI shareholders. The fact that the Quntiles run Clinicals are enrolling at a much faster than expected pace suggests the market penetration might be equally rapid for a condition with obvious unmet needs. If Memantine works it has a known market. A key consideration. An Exchange between an SI NTI shareholder and the CEO: Message 7889317 Message 7889370 BEST WISHES Jeffrey

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next